LYMPHOSEEK®, the first and only receptor-targeted lymphatic mapping agent, works by way of a distinct mechanism of action.1,2,3
As a novel, synthetic soluble solution of tilmanocept, LYMPHOSEEK has a small molecular size (7 nanometers) and carries multiple units of mannose.1-3 This mannose component has a high affinity for receptor proteins known as CD-206, which are found in high concentrations on the surface of macrophages and dendritic cells.1,4 By tightly binding to these mannose receptors, LYMPHOSEEK accumulates in lymphatic tissue within minutes and localizes in tumor-draining lymph nodes.1
LYMPHOSEEK delivers rapid and consistent injection site clearance. In clinical studies, LYMPHOSEEK was detectable in lymph nodes within 10 minutes and up to 30 hours. It is recommended that lymphatic mapping with LYMPHOSEEK be conducted from 15 minutes and up to 15 hours post-injection.1-3
The distinct mechanism of action of LYMPHOSEEK enables reliable identification and localization of lymph nodes draining from a primary tumor.2
References: 1. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2017. 2. Sondak V, King DW, Zager JS, et al. Combined analysis of Phase III trials evaluating Tc99m tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20:680-8. 3. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [99mTc] tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two Phase 3 trials. Ann Surg Oncol. 2013; doi 10.1245/s10434-013-2887-8. 4. Vera, DR, Tokin CA. Tilmanocept: a synthetic receptor-targeted molecule for sentinel lymph node mapping. International Atomic Energy Agency (IAEA) Publication 2014; Chapter X: In Press.